Probiodrug to Present Data from its Phase 2a SAPHIR Study at International Alzheimer’s Disease Conference

Prof. Philipp Scheltens, Principal Investigator of the study, to present at Clinical Trials on Alzheimer’s Disease (CTAD) 2017 in Boston

Management will host a conference call with Dr. Scheltens to discuss the data on 2 November 2017 at 11:00am ET / 16:00 CET

HALLE (SAALE), Germany, 26 October 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced that it will present the data of the Phase 2a SAPHIR Study at CTAD 2017 in Boston, MA, USA.

Prof. Philip Scheltens, MD, PhD, Principal Investigator of the study, will present during the Late Breaking Oral Communications session on Wednesday, 1 November 2017, at 5:45pm EDT in General Ballroom AB of the Boston Park Plaza Hotel. The presentation is entitled “Phase 2a study results with the glutaminylcyclase inhibitor PQ912 in early Alzheimer’s Disease”.

Probiodrug reported topline data of the SAPHIR trial in June (Probiodrug announces encouraging results of the Phase 2a SAPHIR Study)

Based on the rich set of information from the SAPHIR study, Probiodrug has started tailoring a core Phase2b program focusing on optimal-dose finding and longer treatment duration in the early AD patient population. In parallel, partnering discussions will continue (Probiodrug initiates Phase 2b core program of PQ912 and details further strategy).

Webcast and Conference Call
Probiodrug will host a webcast and conference call at which Prof. Philip Scheltens will share the data set and answer questions on Thursday, 2 November 2017 at 11:00am ET (16:00 CET). To participate in the conference call, please call one of the following numbers ten minutes prior to commencement:

Toll-Free Germany: 0 800 182 0040

Toll-Free US & Canada: +1 877-407-6951

International: +1 412-902-0046

To register for the webcast, please visit the Events page at www.probiodrug.de or click here.

###

For more information, please contact:

Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de

Hume Brophy
Conor Griffin, Alexander Protsenko, Jonothan Blackbourn
Tel: +44 (0) 20 7862 6381
Email: probiodrug@humebrophy.com

The Trout Group
Tricia Truehart, Kelly Mueller
Tel: +1 (646) 378-2953
Email: ttruehart@troutgroup.com

MC Services AG
Anne Hennecke, Caroline Bergmann
Tel: +49 (0) 211 529 252 20
Email: probiodrug@mc-services.eu

Notes to Editors:

About Probiodrug AG

Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease (AD). Probiodrug has identified a new therapeutic concept linked to Alzheimer’s disease initiation and progression. The development approaches are targeting a key neuro/synaptotoxic component of the pathology, pyroglutamate-Abeta (pGlu-Abeta, N3pG) as a therapeutic strategy.

Probiodrug’s lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), which has shown therapeutic effects in AD animal models. A Phase 1 study with healthy young and elderly volunteers revealed a dose dependent exposure and showed good safety and tolerability up to the highest dose showing >90% target occupancy in the spinal fluid. In June 2017 Probiodrug announced top-line data of the Phase 2a SAPHIR trial of its lead candidate (Probiodrug announces encouraging results of the Phase 2a SAPHIR Study ). The positive effects seen on secondary exploratory efficacy markers are strongly supporting (a) the hypothesis of pGlu-Abeta being synaptotoxic and (b) the therapeutic concept pursued by Probiodrug. The study revealed a positive benefit risk ratio of PQ912 and provides important guidance how to move forward in the development of PQ912 as a disease-modifying drug for AD. Altogether, the results make the program highly attractive for further development.

Complementary to the small molecule PQ912 inhibiting the formation of the synaptotoxic agent pGlu-Abeta, the company is developing PBD-C06, an anti-pGlu-Abeta-specific monoclonal antibody.The Company has medical use and composition of matter patents related to the inhibition of QC and anti‑pGlu‑Abeta-specific monoclonal antibodies, and has, in the Company’s view, a leading position in this field of research.

Founded in 1997 by Hans-Ulrich Demuth and Konrad Glund, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.

Today, Probiodrug aims to become a leading company in the development of AD treatments and to thereby provide a better life for Alzheimer’s disease patients.

www.probiodrug.de

About Alzheimer’s disease

Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer’s has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.